Clinical and Translational Oncology

, Volume 12, Issue 4, pp 310–314

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN

Authors

    • Medical Oncology DepartmentHospital Universitario Clínico San Carlos
  • Antonio Calles
    • Medical Oncology DepartmentHospital Universitario Clínico San Carlos
  • Pedro Pérez-Segura
    • Medical Oncology DepartmentHospital Universitario Clínico San Carlos
Case Reports

DOI: 10.1007/s12094-010-0510-z

Cite this article as:
Custodio, A., Calles, A. & Pérez-Segura, P. Clin Transl Oncol (2010) 12: 310. doi:10.1007/s12094-010-0510-z

Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.

Keywords

Glioblastoma multiformeRecurrent diseaseEpidermal growth factor receptorPTENTyrosine kinase inhibitors
Download to read the full article text

Copyright information

© Feseo 2010